- Associated Press - Tuesday, January 13, 2015

BOSTON (AP) - Johnson & Johnson has licensed a potential treatment for inflammatory bowel diseases from a company developing therapies that alter interactions between the immune system and microbes in the body.

J&J;’s Janssen Pharmaceutical Companies unit says Vedanta Biosciences of Boston could receive up to $241 million, including an upfront payment and additional ones if a medicine gets approved for a bowel disease such as ulcerative colitis or Crohn’s disease.

The experimental treatment, called VE202, hasn’t been studied in people but has shown effectiveness in animal tests. J&J; will handle future testing.

The two companies could expand the partnership to treatments for additional conditions.

Johnson & Johnson, based in New Brunswick, New Jersey, is a leader in treatments for inflammatory bowel and other immune disorders, selling Remicade, Simponi and Stelara.

Copyright © 2019 The Washington Times, LLC.

The Washington Times Comment Policy

The Washington Times welcomes your comments on Spot.im, our third-party provider. Please read our Comment Policy before commenting.


Click to Read More and View Comments

Click to Hide